Fiduciary Trust’s Verve Therapeutics VERV Stock Holding History

Fiduciary Trust’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-120,000	Closed	-$1.35M	–	878
2025 Q2	$1.35M	Buy	120,000 +40,000	+50%	+$228K	0.02%	344
2025 Q1	$366K	Buy	80,000 +20,000	+33%	+$134K	﹤0.01%	608
2024 Q4	$338K	Buy	60,000 +10,000	+20%	+$56.4K	﹤0.01%	552
2024 Q3	$242K	Buy	50,000 +40,000	+400%	+$232K	﹤0.01%	606
2024 Q2	$48.8K	Hold	10,000	–	–	﹤0.01%	624
2024 Q1	$133K	Hold	10,000	–	–	﹤0.01%	631
2023 Q4	$139K	Buy	+10,000	New	+$124K	﹤0.01%	609

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fiduciary Trust's VERV Position: Q3 2025 in Review

Fiduciary Trust sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 120,000 shares — an estimated $1.35M sold.

Fiduciary Trust first reported a position in VERV in Q4 2023 and held it in 7 quarters. The position peaked at $1.35M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Fiduciary Trust reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Fiduciary Trust sold 120,000 Verve Therapeutics shares in Q3 2025, an estimated $1.35M.
Fiduciary Trust first reported a position in Verve Therapeutics in Q4 2023 and held it in 7 quarters.
Fiduciary Trust's Verve Therapeutics position peaked at $1.35M in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Fiduciary Trust's 13F filing for Q3 2025, filed 14 Nov 2025.